Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis Yuting WangChengpeng ZhangGang Huang Review 30 September 2011 Pages: 357 - 369
Dual HER2-targeted approaches in HER2-positive breast cancer Eugene R. AhnCharles L. Vogel Review 29 September 2011 Pages: 371 - 383
Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b Rupninder SandhuAshley G. RivenbarkWilliam B. Coleman Preclinical study 27 February 2011 Pages: 385 - 399
Influence of stromal–epithelial interactions on breast cancer in vitro and in vivo Shirley M. PotterRoisin M. DwyerMichael J. Kerin Preclinical study 23 February 2011 Pages: 401 - 411
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? K. H. AllisonP. L. KandalaftA. M. Gown Preclinical study 03 March 2011 Pages: 413 - 424
The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models Hong ZhaoKemi CuiStephen T. C. Wong Preclinical study 11 March 2011 Pages: 425 - 436
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Nabila ChaherHugo Arias-PulidoMelanie Royce Preclinical study 01 March 2011 Pages: 437 - 444
miRNA-34a is associated with docetaxel resistance in human breast cancer cells L. KastlI. BrownA. C. Schofield Preclinical study 12 March 2011 Pages: 445 - 454
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment In Hae ParkJungsil RoSeeyeon Lee Preclinical study 25 March 2011 Pages: 455 - 461
The p160 ER co-regulators predict outcome in ER negative breast cancer Melanie SpearsSteffi OesterreichJohn M. S. Bartlett Preclinical study 09 March 2011 Pages: 463 - 472
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer Wenjie Jessie LuZeruesenay DestaDavid A. Flockhart Preclinical Study 09 March 2011 Pages: 473 - 481
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer Yunwei HanZhihao YuXin Wang Clinical Trial 05 October 2011 Pages: 483 - 490
Compliance and persistence of endocrine adjuvant breast cancer therapy Uwe GüthMary Elizabeth MyrickSeraina Margaretha Schmid Clinical Trial 06 October 2011 Pages: 491 - 499
Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread Andreas D. HartkopfMalgorzata BanysTanja Fehm Clinical Trial 05 October 2011 Pages: 501 - 508
Sentinel lymph node analysis in breast cancer: contribution of one-step nucleic acid amplification (OSNA) Florence GodeyJean LevequeCécile Bendavid Athias Clinical trial 13 October 2011 Pages: 509 - 516
Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course Hélène Kolesnikov-GauthierLaurence VanlemmensJacques Bonneterre Clinical Trial 26 October 2011 Pages: 517 - 525
Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes Jiyoung KimSeKyung LeeJung-Hyun Yang Clinical trial 30 October 2011 Pages: 527 - 540
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial Kathleen I. PritchardAlison MunroJohn M. S. Bartlett Clinical trial 01 November 2011 Pages: 541 - 551
Are genetic and environmental components of variance in mammographic density measures that predict breast cancer risk independent of within-twin pair differences in body mass index? Gillian S. DiteJennifer StoneJohn L. Hopper Epidemiology 27 August 2011 Pages: 553 - 559
Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women Azadeh StarkRobert StappAndrew Dick Epidemiology 27 August 2011 Pages: 561 - 570
Body mass index and risk of second primary breast cancer: The WECARE Study Jennifer D. BrooksEsther M. JohnLeslie Bernstein Epidemiology 03 September 2011 Pages: 571 - 580
Aspirin use and breast cancer risk: a meta-analysis Ting LuoHua-Mei YanHong Zheng Epidemiology 04 September 2011 Pages: 581 - 587
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients Jennifer A. LigibelA. James O’MalleyNancy L. Keating Epidemiology 01 September 2011 Pages: 589 - 597
Changes in perceived attentional function in women following breast cancer surgery Mei-Ling ChenChristine MiaskowskiShin-Cheh Chen Epidemiology 07 September 2011 Pages: 599 - 606
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer Jennifer C. LivaudaisDawn L. HershmanGloria D. Coronado Epidemiology 16 September 2011 Pages: 607 - 617
Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy—Breast (FACT-B) in Asian breast cancer patients Raymond NgChun Fan LeeYin Bun Cheung Epidemiology 16 September 2011 Pages: 619 - 625
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance Valesca P. RetèlManuela A. JooreWim H. van Harten Epidemiology 24 September 2011 Pages: 627 - 636
Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project Jeannette M. BeasleyMarilyn L. KwanBette J. Caan Epidemiology 21 September 2011 Pages: 637 - 643
Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location Johanna H. VestjensMaaike de BoerVivianne C. Tjan-Heijnen Epidemiology 17 September 2011 Pages: 645 - 651
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy R. HeinS. AbbasJ. Chang-Claude Epidemiology 23 September 2011 Pages: 653 - 661
Use of high technology imaging for surveillance of early stage breast cancer K. S. PanageasC. S. SimaD. Schrag Epidemiology 24 September 2011 Pages: 663 - 670
The relationship between twin births and maternal risk of breast cancer: a meta-analysis Hye Sook KimOk Hee WooJae Hong Seo Epidemiology 24 September 2011 Pages: 671 - 677
Change in physical activity during active treatment in a prospective study of breast cancer survivors Marilyn L. KwanBarbara SternfeldLawrence H. Kushi Epidemiology 28 September 2011 Pages: 679 - 690
Variation between hospitals in surgical margins after first breast-conserving surgery in the Netherlands Margriet van der Heiden-van der LooLinda de MunckPetra H. Peeters Epidemiology 11 October 2011 Pages: 691 - 698
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms Victoria K. ShanmugamJames McCloskeyJennifer Eng-Wong Brief Report 11 November 2011 Pages: 699 - 708
Effect of simvastatin on the pharmacokinetics of anastrozole Ting BaoAmanda L. BlackfordVered Stearns Brief Report 17 November 2011 Pages: 709 - 711
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity Gabrielle RocqueAdedayo OnitiloMark E. Burkard Brief Report 08 November 2011 Pages: 713 - 721
BRCA1 c.4987-3C>G is a pathogenic mutation Rita D. BrandãoKees E. P. van RoozendaalMarinus J. Blok Letter to the Editor Open access 24 November 2011 Pages: 723 - 725
Erratum to: The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer Gabrielle ColleranNiall McInerneyElinor Sawyer Erratum 29 March 2011 Pages: 727 - 727
Erratum to: Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort N. M. McInerneyN. MillerE. Sawyer Erratum 29 March 2011 Pages: 729 - 729
